Name /REGiMMUNE Limited.
Address /8F-8, 41 Nanjing W. Rd., Datong Dist., Taipei, Taiwan
Name /Kenzo Kosuda
Telephone /+886-2-2555-3377 #503
REGiMMUNE is a clinical-stage biopharmaceutical company focused on creating innovative immunotherapies for rare diseases and cancer by leveraging underexploited biological opportunities. REGiMMUNE specifically target well-characterized biological pathways with compelling scientific data supporting their importance in regulating the immune response against disease. To target new pathways, we are building a robust and highly efficient discovery capability to create and optimize highly differentiated biologic product candidates.
REGiMMUNE focus on a critical cell subset with potent immunomodulation activities, Regulatory T cells (Tregs). Decades of scientific research have demonstrated that Tregs act to control immune responses, which may be beneficial to harness this activity for alleviating autoimmune disease manifestation and for facilitating transplantation tolerance. Our approach for controlling the expansion of Tregs takes advantage of a natural pathway with a synthetic small molecule formulated with liposome technology to treat GvHD. Our lead molecule, RGI-2001, has been well tolerated by patients in phase 1 clinical studies with demonstrated target engagement and measurable pharmacological activity in-vivo to expand Tregs. More recently with Tregs, emerging data in the immuno-oncology field has pointed towards a potent subset of these cells mediating acquired resistance to checkpoint inhibitors and limiting patient responders to bispecific T cell engaging biologics. We are developing antibody therapeutic approaches that will specifically target Tregs and reduce their undesired function in the tumor microenvironment. As the immuno-oncology market evolves toward the use of combination therapies, a key element of our strategy is to build a tailored portfolio of product candidates that target a wide range of complementing immune mechanisms. Consistent with this strategy, we are developing additional antibody drug candidates that may become the foundation for the next generation of combination therapies for immuno-oncology.
Name /Wendy Kao